{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:56:51Z","timestamp":1781661411945,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["1H79TI080271"],"award-info":[{"award-number":["1H79TI080271"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jsat.2019.06.015","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T22:29:58Z","timestamp":1561501798000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs"],"prefix":"10.1016","volume":"108","author":[{"given":"Rachel P.","family":"Winograd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin J.","family":"Stringfellow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ned","family":"Presnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Duello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Rudder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jsat.2019.06.015_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/08897077.2015.1062457","article-title":"Counselor training and attitudes toward pharmacotherapies for opioid use disorder","volume":"37","author":"Aletraris","year":"2016","journal-title":"Substance Abuse"},{"issue":"5","key":"10.1016\/j.jsat.2019.06.015_bb0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.jsat.2019.06.015_bb0015","article-title":"Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence","volume":"10","author":"Amato","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2019.06.015_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes","volume":"52","author":"Bentzley","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.06.015_bb0025","doi-asserted-by":"crossref","unstructured":"Bhatraju, E. P., Grossman, E., Tofighi, B., McNeely, J., DiRocco, D., Flannery, M., \u2026 Lee, J. D. (2017). Public sector low threshold office-based buprenorphine treatment: Outcomes at year 7. Addiction Science & Clinical Practice, 12(1), 7. doi:https:\/\/doi.org\/10.1186\/s13722-017-0072-2.","DOI":"10.1186\/s13722-017-0072-2"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.015_bb0030","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: Development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2019.06.015_bb0035","author":"Brooks"},{"key":"10.1016\/j.jsat.2019.06.015_bb0040","author":"Bureau of Vital Statistics Missouri Department of Health and Senior Services"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.015_bb0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1748-5908-8-117","article-title":"The dynamic sustainability framework: Addressing the paradox of sustainment amid ongoing change","volume":"8","author":"Chambers","year":"2013","journal-title":"Implementation Science: IS"},{"key":"10.1016\/j.jsat.2019.06.015_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","author":"Cicero","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.015_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder","volume":"23","author":"Connery","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.015_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ADM.0b013e31829727b2","article-title":"Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes","volume":"7","author":"Cunningham","year":"2013","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2019.06.015_bb0065","first-page":"1","article-title":"Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?","author":"Doernberg","year":"2019","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2019.06.015_bb0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.drugalcdep.2017.01.016","article-title":"Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial","volume":"174","author":"Dunlop","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.015_bb0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1370\/afm.2098","article-title":"Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: A 7-year cohort study","volume":"15","author":"Dupouy","year":"2017","journal-title":"The Annals of Family Medicine"},{"issue":"12","key":"10.1016\/j.jsat.2019.06.015_bb0080","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care\u2013based buprenorphine taper vs maintenance therapy for prescription opioid dependence","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"9","key":"10.1016\/j.jsat.2019.06.015_bb0085","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamainternmed.2018.3504","article-title":"Implementing opioid agonist treatment in correctional facilities","volume":"178","author":"Fiscella","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.015_bb0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13722-014-0023-0","article-title":"Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: A qualitative study of the perceptions of former inmates with opioid use disorder","volume":"10","author":"Fox","year":"2015","journal-title":"Addiction Science & Clinical Practice"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.015_bb0095","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","article-title":"Policy pathways to address provider workforce barriers to buprenorphine treatment","volume":"54","author":"Haffajee","year":"2018","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.jsat.2019.06.015_bb0100","unstructured":"Henry J Kaiser Family Foundation. (2019). Opioid overdose death rates and all drug overdose death rates per 100,000 population (age-adjusted). Retrieved February 5, 2019, from https:\/\/www.kff.org\/other\/state-indicator\/opioid-overdose-death-rates\/?currentTimeframe=1&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D."},{"issue":"8","key":"10.1016\/j.jsat.2019.06.015_bb0105","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/add.14188","article-title":"The impact of buprenorphine and methadone on mortality: A primary care cohort study in the United Kingdom","volume":"113","author":"Hickman","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.06.015_bb0110","author":"Hinde"},{"key":"10.1016\/j.jsat.2019.06.015_bb0115","author":"Hospital Industry Data Institute"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.015_bb0120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.015_bb0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0740-5472(03)00130-2","article-title":"Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS)","volume":"25","author":"Hubbard","year":"2003","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.06.015_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren't physicians prescribing more buprenorphine","volume":"78","author":"Huhn","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.015_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Annals of Family Medicine"},{"issue":"5","key":"10.1016\/j.jsat.2019.06.015_bb0140","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2019.06.015_bb0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jsat.2017.04.017","article-title":"The relationship between diversion-related attitudes and sharing and selling buprenorphine","volume":"78","author":"Kenney","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"30","key":"10.1016\/j.jsat.2019.06.015_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/adaw.32055","article-title":"SAMHSA's McCance-Katz says no to \u2018medication alone\u2019","volume":"30","author":"Knopf","year":"2018","journal-title":"Alcoholism & Drug Abuse Weekly"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.015_bb0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1176\/appi.ps.201100034","article-title":"Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders","volume":"63","author":"Knudsen","year":"2012","journal-title":"Psychiatric Services"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.015_bb0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.evalprogplan.2011.02.004","article-title":"Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure","volume":"34","author":"Knudsen","year":"2011","journal-title":"Evaluation and Program Planning"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.015_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsat.2005.05.002","article-title":"Buprenorphine diffusion: The attitudes of substance abuse treatment counselors","volume":"29","author":"Knudsen","year":"2005","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2019.06.015_bb0170","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/10550490701525418","article-title":"Research network involvement and addiction treatment center staff: Counselor attitudes toward buprenorphine","volume":"16","author":"Knudsen","year":"2007","journal-title":"American Journal on Addictions"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.015_bb0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2149","article-title":"Primary care\u2013based models for the treatment of opioid use disorder","volume":"166","author":"Korthuis","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"10118","key":"10.1016\/j.jsat.2019.06.015_bb0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.jsat.2019.06.015_bb0185","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.015_bb0190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.11613\/BM.2013.018","article-title":"The chi-square test of independence","volume":"23","author":"McHugh","year":"2013","journal-title":"Biochemia Medica"},{"key":"10.1016\/j.jsat.2019.06.015_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001333.pub3","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"2","author":"Minozzi","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2019.06.015_bb0200","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.06.015_bb0205","author":"National Institute on Drug Abuse"},{"issue":"8","key":"10.1016\/j.jsat.2019.06.015_bb0210","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1377\/hlthaff.2012.0846","article-title":"A call for evidence-based medical treatment of opioid dependence in the United States and Canada","volume":"32","author":"Nosyk","year":"2013","journal-title":"Health Affairs"},{"key":"10.1016\/j.jsat.2019.06.015_bb0215","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2015.08.007","article-title":"Buprenorphine infrequently found in fatal overdose in New York City","volume":"155","author":"Paone","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.015_bb0220","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.drugalcdep.2009.07.013","article-title":"Long-term outcomes of office-based buprenorphine\/naloxone maintenance therapy","volume":"106","author":"Parran","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.06.015_bb0225","author":"Pearson"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.015_bb0230","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jsat.2011.05.005","article-title":"A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment","volume":"41","author":"Rieckmann","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.jsat.2019.06.015_bb0235","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.addbeh.2011.01.032","article-title":"Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation","volume":"36","author":"Roman","year":"2011","journal-title":"Addictive Behaviors"},{"issue":"3","key":"10.1016\/j.jsat.2019.06.015_bb0240","doi-asserted-by":"crossref","first-page":"413","DOI":"10.15288\/jsad.2012.73.413","article-title":"Advancing recovery: Implementing evidence-based treatment for substance use disorders at the systems level","volume":"73","author":"Schmidt","year":"2012","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.015_bb0245","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","article-title":"A randomized controlled trial of interim methadone maintenance","volume":"63","author":"Schwartz","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"25","key":"10.1016\/j.jsat.2019.06.015_bb0250","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1610047","article-title":"Interim buprenorphine vs. waiting list for opioid dependence","volume":"375","author":"Sigmon","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2019.06.015_bb0255","doi-asserted-by":"crossref","unstructured":"Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., \u2026 Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ (Clinical Research Ed.), 357, j1550. doi:https:\/\/doi.org\/10.1136\/bmj.j1550.","DOI":"10.1136\/bmj.j1550"},{"issue":"33","key":"10.1016\/j.jsat.2019.06.015_bb0260","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/adaw.32087","article-title":"Letter to the editor: \u2018Medication first\u2019 not the same as \u2018medication only\u2019","volume":"30","author":"Stringer","year":"2018","journal-title":"Alcoholism & Drug Abuse Weekly"},{"key":"10.1016\/j.jsat.2019.06.015_bb0265","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.jsat.2019.06.015_bb0270","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.015_bb0275","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2019.06.015_bb0280","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.addbeh.2019.01.020","article-title":"Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City","volume":"93","author":"Truong","year":"2019","journal-title":"Addictive Behaviors"},{"issue":"4","key":"10.1016\/j.jsat.2019.06.015_bb0285","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2105\/AJPH.94.4.651","article-title":"Housing first, consumer choice, and harm reduction for homeless individuals with a dual diagnosis","volume":"94","author":"Tsemberis","year":"2004","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2019.06.015_bb0290","author":"U.S. Food & Drug Administration Center for Drug Evaluation and Research"},{"key":"10.1016\/j.jsat.2019.06.015_bb0295","author":"University of Cambridge MRC Cognition and Brain Sciences Unit"},{"issue":"2","key":"10.1016\/j.jsat.2019.06.015_bb0300","first-page":"101","article-title":"A critique and improvement of the CL common language effect size statistics of McGraw and Wong","volume":"25","author":"Vargha","year":"2000","journal-title":"Journal of Educational and Behavioral Statistics Summer"},{"issue":"1","key":"10.1016\/j.jsat.2019.06.015_bb0305","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12954-017-0135-4","article-title":"The north American opioid epidemic: Current challenges and a call for treatment as prevention","volume":"14","author":"Vashishtha","year":"2017","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.jsat.2019.06.015_bb0310","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.06.015_bb0315","doi-asserted-by":"crossref","DOI":"10.1080\/00952990.2019.1605372","article-title":"The case for a medication first approach to the treatment of opioid use disorder","author":"Winograd","year":"2019","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2019.06.015_bb0320","author":"World Health Organization"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219301205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219301205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:25:19Z","timestamp":1777573519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547219301205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":64,"alternative-id":["S0740547219301205"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.06.015","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}